In this issue of Clinical Cancer Research, the articles by Deniger and colleagues (1) and by Fisher and colleagues (2) report on a novel process for scaling up in vitro expansion of polyclonal gd T-cell lines with killing activity against cancer cells for clinical use. T-cell therapy to treat cancer has been the focus of much interest in the past years and led to the recent success of chimeric antigen receptors-expressing T cells (reviewed in ref. 3) . This interest mainly concentrated on ab T cells whose mode of antigen recognition, and thus of activation, has been fully resolved. Because of their ability to recognize different stress signals provided by tumor cells, gd T cells also hold an alternative promise in cancer therapy. So far, much attention has been given to the predominant subset of circulating gd T cells, the Vg9Vd2 T cells, which are strongly activated by nonpeptide phosphorylated metabolites of isoprenoid biosynthesis pathway (called phosphoantigens). Phosphoantigens are produced at high levels by tumor cells and have been successfully used to generate clinical scale quantities of Vg9Vd2 T cells in vitro and to expand them in vivo in active vaccination-type trials. Although remarkably safe and superior to current secondline therapies in some settings, Vg9Vd2 T-cell-based trials in patients with cancer provided mixed results, suggesting room for improvement in the therapeutical use of gd T cells (4) .
Besides Vg9Vd2 T cells, all the other gd T cells (collectively called Vd2 neg gd T cells) populate many epithelial tissues where they represent an important component of intraepithelial lymphocytes, so likely the main subset of human gd T cells in the whole body, and an important first-line defense against diverse host assaults. Despite increasing evidence of their role in tumor surveillance, Vd2 neg gd T cells have been largely neglected in cancer cell therapy because of the limited knowledge about the antigens they recognize, which have restricted their specific and large-scale expansion for clinical purposes. One method to grow large quantities of whole gd T cells was developed by Lopez and colleagues (5) but has not yet been used in cell therapy trials.
Deniger and colleagues (1) 11 from cord blood). Although ex vivo stimulation of Vg9Vd2 T cells from patients with cancer is often limited using phosphoantigens, Fisher and colleagues (2) also obtained high expansion rate of gd T cells from children with neuroblastoma with this aAPC-based protocol. Using either mRNA quantification through nonenzymatic digital multiplex assay (i) or next-generation sequencing (ii), both teams performed in-depth gd T-cell receptor (TCR) TCR repertoire analysis of the generated gd T-cell lines. Although not exactly reflecting the initial composition of gd T cells, the repertoire of expanded T cells was polyclonal with expression of all functional Vd and Vg chains.
It is not yet clear which are the activation signals underpinning this large expansion of polyclonal gd T cells in this process. Proliferation was dependent on CD137L, IL2, and IL21, but the involvement of TCR signaling has not been tested. Although it is hard to conceive that aAPCs express the full array of TCR ligands for all expanded gd T cells, engagement of TCR is suggested by the low TCR expression on generated Vd2 pos T cells and by the importance of CD137L for the expansion despite the absence of CD137 expression by gd T cells prior expansion. Fisher and colleagues who coated B1 anti-gdTCR antibody on aAPCs showed it did not have a major role in gd T-cell expansion even if this led to a better representation of Vd2 neg subsets. Gamma delta T cells have been shown to express HLA-I inhibitory receptors (7), so the absence of HLA-I expression by K562 as well as expression of activatory molecules such as NKG2D ligands may also play critical role in gd T-cell activation. Most interestingly, aAPC-propagated gd T cells displayed efficient response against cancer cells, with an equivalent contribution of Vd2 pos and Vd2 neg gd T cells. A strikingly broad killing capacity against tumor cell lines from acute or chronic leukemia, colon, pancreatic, and ovarian cancers was developed, whereas no killing of autologous or allogeneic normal B cells ensued. This panel of targets was extended to neuroblastoma cell lines in Fisher and colleagues article, which also reports on an enhanced killing in the presence of an anti-ganglioside G2 mAb consistent with the expression of CD16 on a significant proportion of aAPCexpanded Vd2 pos cells. Tumor killing was accompanied by IFNg production, which could be an additional mean for gd T cells to control tumors.
To test whether polyclonal gd T cells are able to kill tumors in vivo, Deniger and colleagues (1) used an ovarian cancer xenograft model in immunodeficient mice and in vivo bioluminescence imaging. The bioburdens of established tumors were considerably reduced 72 days after injection of polyclonal or separate subsets of expanded gd T cells, resulting in an increased long-term survival of mice.
Further investigations are needed to understand how aAPC-generated gd T cells recognize and kill cancer cells. Combined blocking of NKG2D, DNAM1, and the TCR decreased cancer cell killing, suggesting a complex multimolecular-based cancer cell recognition by gd T cells. Antigen recognition by polyclonal gd TCRs on such a broad spectrum of cancer cells raises the question of their frequency and specificity, opening perspectives for identification of new gd TCR ligands.
These results have strong potential for translation in clinical practice. The aAPC-mediated expansion procedure and reagents have already been approved for clinical use. (9) . Expression of CD16 on Vd2 pos cells also paves the way for combined therapy with therapeutic antibodies. Finally, the widely reported involvement of gd T cells in the protection against infections might provide collateral benefit of their injection in patients with cancer susceptible to infectious diseases because of chemotherapy.
Clinical trials using aAPC-generated gd T cells should also shed light on still pending but interesting issues: Are these cells able to migrate into the tumors? Can they expand in vivo after infusion? Is quantity of infused cells a major issue or could therapeutic potential be improved by increasing their specificity toward defined tumors or defined antigens? Altogether with the previously reported association between Vd1 subset expansion and complete response in hematopoietic stem cell transplantation patients with leukemia (10), and the mitigated but encouraging results obtained from Vg9Vd2 T-cell-based cancer therapy, the infusion of polyclonal gd T cells with broad cancer specificity deserves deep attention as a valuable additional tool in the therapeutical arsenal against cancer.
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